Benitec Biopharma Inc.

NasdaqCM BNTC

Benitec Biopharma Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 61.92 M

Benitec Biopharma Inc. Net Cash Used Provided By Financing Activities is USD 61.92 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 122.68% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Benitec Biopharma Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 27.81 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqCM: BNTC

Benitec Biopharma Inc.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
IPO Date	June 24, 2014
Location	United States
Headquarters	3940 Trust Way
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key trends

Past 5 years